First detection of a VIM-1 metallo-beta-lactamase in a carbapenem-resistant Citrobacter freundii clinical isolate in an acute hospital in Germany

Jan Weile; Harald Rahmig; Sabine Gfröer; Klaus Schroeppel; Cornelius Knabbe; Milorad Susa

doi:10.1080/00365540600868388

First detection of a VIM-1 metallo-beta-lactamase in a carbapenem-resistant Citrobacter freundii clinical isolate in an acute hospital in Germany

Scand J Infect Dis. 2007;39(3):264-6. doi: 10.1080/00365540600868388.

Authors

Jan Weile¹, Harald Rahmig, Sabine Gfröer, Klaus Schroeppel, Cornelius Knabbe, Milorad Susa

Affiliation

¹ Department of Clinical Chemistry and Laboratory Medicine, Robert Bosch Hospital, Stuttgart, Germany. jan.weile@ikp-stuttgart.de

PMID: 17366062
DOI: 10.1080/00365540600868388

Abstract

We report the first detection of a carbapenem-resistant Citrobacter freundii clinical strain in Germany. It was isolated from an abscess of a patient with acute necrotic pancreatitis in an acute hospital. PCR and sequencing experiments revealed that the carbapenem resistance was mediated by a VIM-1 metallo-beta-lactamase, located on a plasmid encoded class 1 integron. Carbapenem resistance in Enterobacteriaceae is so far a rare event and 1 of the major therapeutic concerns in the future.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged, 80 and over
Carbapenems / pharmacology*
Cilastatin / therapeutic use
Ciprofloxacin / therapeutic use
Citrobacter freundii / drug effects
Citrobacter freundii / enzymology*
Citrobacter freundii / genetics
Citrobacter freundii / isolation & purification
Enterobacteriaceae Infections / drug therapy
Enterobacteriaceae Infections / microbiology
Female
Germany
Humans
Imipenem / therapeutic use
Polymerase Chain Reaction / methods
beta-Lactam Resistance / genetics
beta-Lactamases / genetics
beta-Lactamases / metabolism

Substances

Carbapenems
Cilastatin
Ciprofloxacin
Imipenem
VIM-1 metallo-beta-lactamase
beta-Lactamases